Abstract:Pancreatic ductal adenocarcinoma (PDAC) stands as one of the most lethal cancers, marked by rapid progression, pronounced chemoresistance, and a complex network of genetic and epigenetic dysregulation. Within this challenging context, sirtuins, NAD+-dependent deacetylases, have emerged as pivotal modulators of key cellular processes that drive pancreatic cancer progression. Each sirtuin contributes uniquely to PDAC pathogenesis. SIRT1 influences apoptosis and chemoresistance through hypoxia, enhancing glycolytic metabolism and HIF-1α signaling, which sustain tumor survival against drugs like gemcitabine. SIRT2, conversely, disrupts cancer cell proliferation by inhibiting eIF5A, while SIRT3 exerts tumor-suppressive effects by regulating mitochondrial ROS and glycolysis. SIRT4 inhibits aerobic glycolysis, and its therapeutic upregulation has shown promise in curbing PDAC progression. Furthermore, SIRT5 modulates glutamine and glutathione metabolism, offering an avenue to disrupt PDAC's metabolic dependencies. SIRT6 and SIRT7, through their roles in angiogenesis, EMT, and metastasis, represent additional targets, with modulators of SIRT6, such as JYQ-42, showing potential to reduce tumor invasiveness. This review aims to provide a comprehensive exploration of the emerging roles of sirtuins, a family of NAD+-dependent enzymes, as critical regulators within the oncogenic landscape of pancreatic cancer. This review meticulously explores the nuanced involvement of sirtuins in pancreatic cancer, elucidating their contributions to tumorigenesis and suppression through mechanisms such as metabolic reprogramming, the maintenance of genomic integrity and epigenetic modulation. Furthermore, it emphasizes the urgent need for the development of targeted therapeutic interventions aimed at precisely modulating sirtuin activity, thereby enhancing therapeutic efficacy and optimizing patient outcomes in the context of pancreatic malignancies.

SIRT1 and gynecological malignancies

SIRT1 and Gynecological Malignancies (Review)

SIRT1 Facilitates Hepatocellular Carcinoma Metastasis by Promoting PGC-1α-mediated Mitochondrial Biogenesis.

Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress.

Recent Advances of SIRT1 and Implications in Chemotherapeutics Resistance in Cancer.

Gene Expression and Prognosis of Sirtuin Family Members in Ovarian Cancer

Targeting Sirtuins for Cancer Therapy: Epigenetics Modifications and Beyond

Sirtuin1 expression and survival in endometrial and clear-cell uterine cancer

Role of SIRT1 in Hematologic Malignancies.

The Clinical Significance of SIRT2 in Malignancies: A Tumor Suppressor or an Oncogene?

Regulation of SIRT1 in Ovarian Function: PCOS Treatment.

Sirtuins as Key Regulators in Pancreatic Cancer: Insights into Signaling Mechanisms and Therapeutic Implications

SIRT1 and p53, effect on cancer, senescence and beyond.

Multifaceted Modulation of SIRT1 in Cancer and Inflammation.

Cytoplasmic SIRT1 Inhibits Cell Migration and Invasion by Impeding Epithelial–mesenchymal Transition in Ovarian Carcinoma

SIRT1: a Potential Tumour Biomarker and Therapeutic Target.

SIRT1 induces resistance to apoptosis in human granulosa cells by activating the ERK pathway and inhibiting NF-κB signaling with anti-inflammatory functions

SIRT1 mediates breast cancer development and tumorigenesis controlled by estrogen-related receptor β

The Role of SIRT1 on DNA Damage Response and Epigenetic Alterations in Cancer

The role of SIRT1 in tumorigenesis.

SIRT1 is involved in oncogenic signaling mediated by GPER in breast cancer